Jeonghun Kim

Jeonghun Kim

Auto-generated profile, based on publicly available information

Jeonghun Kim

Department of Microbiology, Vaccine Innovation Center, Biosafety Center, College of Medicine, Korea University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDoyeon Kim
Doyeon Kim
SKSukjun Kim
Sukjun Kim
JPJoori Park
Joori Park
HCHee Ryung Chang
Hee Ryung Chang
JCJeeyoon Chang
Jeeyoon Chang
DBDaehyun Baek
Daehyun Baek
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which infected >200 million people resulting in >4 million deaths. However, temporal landscape of the SARS-CoV-2 translatome and its impact on the human genome remain unexplored. Here, we report a high-resolution atlas of the translatome and transcriptome of SARS-CoV-2 for various time points after infecting human cells. Intriguingly, substantial amount of SARS-CoV-2 translation initiates at a novel translation initiation site (TIS) located in the leader sequence, termed TIS-L. Since TIS-L is included in all the genomic and subgenomic RNAs, the SARS-CoV-2 translatome may be regulated by a sophisticated interplay between TIS-L and downstream TISs. TIS-L functions as a strong translation enhancer for ORF S, and as translation suppressors for most of the other ORFs. Our global temporal atlas provides compelling insight into unique regulation of the SARS-CoV-2 translatome and helps comprehensively evaluate its impact on the human genome.

4 July 2022 in Cell Reports
Verified
Journal Article
Open access
JSJu-Ri Sim
Ju-Ri Sim
DSDong Hoon Shin
Dong Hoon Shin
PPPil-Gu Park
Pil-Gu Park
SPSo-Hyeon Park
So-Hyeon Park
JBJoon-Yong Bae
Joon-Yong Bae
MLMin Goo Lee
Min Goo Lee
As an enveloped virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delivers its viral genome into host cells via fusion of the viral and cell membranes. Here, we show that ANO6/TMEM16F-mediated cell surface exposure of phosphatidylserine is critical for SARS-CoV-2 entry and that ANO6-selective inhibitors are effective against SARS-CoV-2 infections. Application of the SARS-CoV-2 Spike pseudotyped virus (SARS2-PsV) evokes a cytosolic Ca2+ elevation and ANO6-dependent phosphatidylserine externalization in ACE2/TMPRSS2-positive mammalian cells. A high-throughput screening of drug-like chemical libraries identifies three different structural classes of chemicals showing ANO6 inhibitory effects. Among them, A6-001 displays the highest potency and ANO6 selectivity and it inhibits the single-round infection of SARS2-PsV in ACE2/TMPRSS2-positive HEK 293T cells. More importantly, A6-001 strongly inhibits authentic SARS-CoV-2-induced phosphatidylserine scrambling and SARS-CoV-2 viral replications in Vero, Calu-3, and primarily cultured human nasal epithelial cells. These results provide mechanistic insights into the viral entry process and offer a potential target for pharmacological intervention to protect against coronavirus disease 2019 (COVID-19).

5 August 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYoonjung Kim
Yoonjung Kim
JBJoon-Yong Bae
Joon-Yong Bae
KKKi Tae Kwon
Ki Tae Kwon
HCHyun-Ha Chang
Hyun-Ha Chang
WLWon Kee Lee
Won Kee Lee
SKShin-Woo Kim
Shin-Woo Kim
Knowledge of the factors affecting the difference in kinetics and longevity of the neutralizing antibody (nAb) response to SARS-CoV-2 is necessary to properly prioritize vaccination. In the present study, from March to December 2020, of the 143 patients who recovered from COVID-19, 87 underwent study visits scheduled every 3 months. Patient demographics and blood samples were collected followed by a plaque reduction neutralization test to analyze nAb titers. A linear mixed model was used to compare the effects of sex, age, and disease severity over time. Results demonstrated a gradual reduction in nAb titers over time with a significant decrease from 6 to 9 months post-COVID-19 infection (p < 0.001). In time-to-sex, age, and disease severity comparisons, reduction in nAb titers over time was unaffected by sex (p = 0.167), age (p = 0.188), or disease severity (p = 0.081). Additionally, the nAb titer was 1.46 times significantly higher in those aged ≥ 50 years than in those aged < 50 years (p = 0.036) irrespective of time Moreover, the nAb titer was 2.41 times higher in the moderate or above than that in the below moderate disease severity group (p < 0.001). However, no significant differences were observed in terms of sex (p = 0.300). Given the reduction in nAbs over time, maintaining protective neutralizing antibodies regardless of sex, age, or disease severity is needed.

18 January 2023 in Journal of Infection
Verified
Journal Article
Closed access
SKSung-Woon Kang
Sung-Woon Kang
HPHeedo Park
Heedo Park
JKJi Yeun Kim
Ji Yeun Kim
SLSo Yun Lim
So Yun Lim
SLSohyun Lee
Sohyun Lee
SKSung-Han Kim
Sung-Han Kim

23 December 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
JKJin Il Kim
Jin Il Kim
SPSehee Park
Sehee Park
JBJoon-Yong Bae
Joon-Yong Bae
SLSunmi Lee
Sunmi Lee
JKJeonghun Kim
Jeonghun Kim
MPMan-Seong Park
Man-Seong Park
Zoonotic avian influenza viruses pose severe health threats to humans. Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate. Vaccination of poultry appears to reduce human infections. However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics. To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes. Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity. Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs. In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines. In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy. These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.

1 January 2023 in Immune Network
Verified
Journal Article
Open access
PDF file
ENEliel Nham
Eliel Nham
JKJineui Kim
Jineui Kim
JLJungmin Lee
Jungmin Lee
HPHeedo Park
Heedo Park
JKJeonghun Kim
Jeonghun Kim
JNJi Yun Noh
Ji Yun Noh
Nham E, et al. Immune Netw. 2023 Nov;23(6):e43. https://doi.org/10.4110/in.2023.23.e43